MX2017005659A - Nuevos compuestos de metil-piperidina utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. - Google Patents
Nuevos compuestos de metil-piperidina utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.Info
- Publication number
- MX2017005659A MX2017005659A MX2017005659A MX2017005659A MX2017005659A MX 2017005659 A MX2017005659 A MX 2017005659A MX 2017005659 A MX2017005659 A MX 2017005659A MX 2017005659 A MX2017005659 A MX 2017005659A MX 2017005659 A MX2017005659 A MX 2017005659A
- Authority
- MX
- Mexico
- Prior art keywords
- synthase
- compounds useful
- piperidine compounds
- microsomal prostaglandin
- novel methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente invención se refiere a compuestos de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde R, R1 y G son como se describen en la presente; métodos para preparar los compuestos; y uso de los compuestos para tratar dolor y/o inflamación asociada con artritis u osteoartritis. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462072196P | 2014-10-29 | 2014-10-29 | |
| PCT/US2015/056960 WO2016069376A1 (en) | 2014-10-29 | 2015-10-22 | Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017005659A true MX2017005659A (es) | 2017-06-26 |
Family
ID=54478248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017005659A MX2017005659A (es) | 2014-10-29 | 2015-10-22 | Nuevos compuestos de metil-piperidina utiles para inhibir la sintasa-1 de prostaglandina microsomal e2. |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9962375B2 (es) |
| EP (1) | EP3230278B1 (es) |
| JP (1) | JP6393830B2 (es) |
| KR (1) | KR101898829B1 (es) |
| CN (1) | CN107074829B (es) |
| AR (1) | AR102362A1 (es) |
| AU (1) | AU2015339644B2 (es) |
| CA (1) | CA2963321C (es) |
| CL (1) | CL2017001017A1 (es) |
| CY (1) | CY1122534T1 (es) |
| DK (1) | DK3230278T3 (es) |
| EA (1) | EA032428B1 (es) |
| ES (1) | ES2773439T3 (es) |
| HR (1) | HRP20200216T1 (es) |
| HU (1) | HUE047895T2 (es) |
| JO (1) | JO3581B1 (es) |
| LT (1) | LT3230278T (es) |
| MX (1) | MX2017005659A (es) |
| NZ (1) | NZ730724A (es) |
| PL (1) | PL3230278T3 (es) |
| PT (1) | PT3230278T (es) |
| RS (1) | RS59783B1 (es) |
| SI (1) | SI3230278T1 (es) |
| TW (1) | TWI605039B (es) |
| WO (1) | WO2016069376A1 (es) |
| ZA (1) | ZA201702198B (es) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
| JP7305654B2 (ja) * | 2018-01-09 | 2023-07-10 | ブリガム・ヤング・ユニバーシティ | ウォゴニンで疼痛を治療するための組成物および方法 |
| CN108558806B (zh) * | 2018-05-31 | 2020-04-17 | 南京药石科技股份有限公司 | 一种5-氧代-四氢吡喃-3-羧酸酯的关键中间体及其制备方法 |
| WO2020061475A2 (en) * | 2018-09-21 | 2020-03-26 | The Johns Hopkins University | Compositions and methods for treating metabolic disorders |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CR20220303A (es) | 2019-12-24 | 2022-09-02 | Gilead Sciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
| CN117964757A (zh) | 2020-02-14 | 2024-05-03 | 吉利德科学公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| IL297327A (en) | 2020-05-01 | 2022-12-01 | Gilead Sciences Inc | 4,2-deoxypyrimidine compounds that inhibit cd73 |
| WO2022039563A1 (en) * | 2020-08-21 | 2022-02-24 | Kanaph Therapeutics Inc. | Novel compounds having inhibitory activity on prostaglandin e2 receptor and uses thereof |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024522594A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| KR20240097895A (ko) | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| IL313831A (en) | 2021-12-28 | 2024-08-01 | Nippon Shinyaku Co Ltd | Indazole compound and pharmaceutical preparation |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355010B1 (en) * | 1999-03-31 | 2002-03-12 | Coaxia, Inc. | Intravascular spinal perfusion and cooling for use during aortic surgery |
| ATE556067T1 (de) * | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| US20050239921A1 (en) * | 2004-04-27 | 2005-10-27 | Birmingham John N | Preparation of organic additive-treated, pyrogenic silica-encapsulated titanium dioxide particles |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2011023812A1 (en) | 2009-08-27 | 2011-03-03 | Novasaid Ab | Microsomal prostaglandin e synthase-1 (mpges1) inhibitors |
| WO2011048004A1 (en) * | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| WO2013146970A1 (ja) * | 2012-03-29 | 2013-10-03 | 第一三共株式会社 | 新規キノリン誘導体 |
| CA2916101A1 (en) * | 2013-06-20 | 2014-12-24 | Novasaid Ab | Piperidinyl benzoimidazole derivatives as mpge-1 inhibitors |
| AR102361A1 (es) | 2014-10-29 | 2017-02-22 | Lilly Co Eli | Compuestos de metil-quinolina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 |
-
2015
- 2015-10-18 JO JOP/2015/0256A patent/JO3581B1/ar active
- 2015-10-19 TW TW104134250A patent/TWI605039B/zh active
- 2015-10-19 AR ARP150103382A patent/AR102362A1/es unknown
- 2015-10-22 SI SI201531036T patent/SI3230278T1/sl unknown
- 2015-10-22 JP JP2017522866A patent/JP6393830B2/ja active Active
- 2015-10-22 LT LTEP15791432.6T patent/LT3230278T/lt unknown
- 2015-10-22 NZ NZ730724A patent/NZ730724A/en unknown
- 2015-10-22 EP EP15791432.6A patent/EP3230278B1/en active Active
- 2015-10-22 US US15/520,462 patent/US9962375B2/en active Active
- 2015-10-22 AU AU2015339644A patent/AU2015339644B2/en active Active
- 2015-10-22 ES ES15791432T patent/ES2773439T3/es active Active
- 2015-10-22 DK DK15791432.6T patent/DK3230278T3/da active
- 2015-10-22 PT PT157914326T patent/PT3230278T/pt unknown
- 2015-10-22 MX MX2017005659A patent/MX2017005659A/es active IP Right Grant
- 2015-10-22 PL PL15791432T patent/PL3230278T3/pl unknown
- 2015-10-22 EA EA201790766A patent/EA032428B1/ru not_active IP Right Cessation
- 2015-10-22 CA CA2963321A patent/CA2963321C/en active Active
- 2015-10-22 WO PCT/US2015/056960 patent/WO2016069376A1/en active Application Filing
- 2015-10-22 CN CN201580058595.9A patent/CN107074829B/zh active Active
- 2015-10-22 HU HUE15791432A patent/HUE047895T2/hu unknown
- 2015-10-22 RS RS20200015A patent/RS59783B1/sr unknown
- 2015-10-22 KR KR1020177011303A patent/KR101898829B1/ko active IP Right Grant
-
2017
- 2017-03-29 ZA ZA2017/02198A patent/ZA201702198B/en unknown
- 2017-04-24 CL CL2017001017A patent/CL2017001017A1/es unknown
-
2018
- 2018-05-07 US US15/972,699 patent/US20180250282A1/en not_active Abandoned
-
2020
- 2020-01-29 CY CY20201100076T patent/CY1122534T1/el unknown
- 2020-02-11 HR HRP20200216TT patent/HRP20200216T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ730724A (en) | Novel methyl-piperidine compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| PH12018502102A1 (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
| JO3466B1 (ar) | مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6 | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| NZ746825A (en) | Oxysterols and methods of use thereof | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| MX2016005128A (es) | Derivados de 5,6,7,8-tetahidro-5,8-metanocinolina como moduladores del receptor huerfano y relacionado con acido retinoico (rorc) para el tratamiento de enfermedades autoinmunes. | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| MX2016002718A (es) | Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc). | |
| PH12014501712B1 (en) | Novel morpholinyl derivatives useful as mogat-2-inhibitors | |
| PH12016501997B1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
| MY184366A (en) | Pyrazines modulators of gpr6 | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| AU2016330503A8 (en) | Therapeutic compounds and methods of use thereof | |
| MX2018015269A (es) | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. | |
| PH12017500492A1 (en) | Crystalline bace inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |